289 related articles for article (PubMed ID: 30443817)
1. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
3. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding.
Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM
J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443
[TBL] [Abstract][Full Text] [Related]
4. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
[TBL] [Abstract][Full Text] [Related]
5. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
6. Modified version of the American College of Cardiology's recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal.
Gilbert BW; Morton L; Huffman JB; Roemer K; Potter A; Cassidy CD; Vasquez DG
Am J Emerg Med; 2020 Apr; 38(4):806-809. PubMed ID: 31864879
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
8. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
Yohe AS; Livings SE
Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
[TBL] [Abstract][Full Text] [Related]
9. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
[TBL] [Abstract][Full Text] [Related]
10. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.
Fuh L; Goldstein JN; Hayes BD
J Thromb Thrombolysis; 2020 Jul; 50(1):217-220. PubMed ID: 31707622
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
12. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
15. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
16. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
Santibanez M; Lesch CA; Lin L; Berger K
J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
[TBL] [Abstract][Full Text] [Related]
18. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
Yasaka M; Sakata T; Naritomi H; Minematsu K
Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal.
Voils SA; Holder MC; Premraj S; Catlin JR; Allen BR
Thromb Res; 2015 Sep; 136(3):595-8. PubMed ID: 26233569
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy.
Huynh TK; Costello JL; Rebuck JA
Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
